β-Adrenergic Regulation of the Cardiac Na+-K+ ATPase Mediated by Oxidative Signaling

Trends in Cardiovascular Medicine

Volumn 22, Issue 4, 2012, Pages 83-87

  Galougahi, Keyvan Karimi ^a,b   Liu, Chia Chi ^a   Bundgaard, Henning ^c   Rasmussen, Helge H ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANGIOTENSIN II; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL L TYPE; CATECHOLAMINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; FORSKOLIN; GLUTATHIONE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANYLATE CYCLASE; ISOPRENALINE; METOPROLOL; MITOCHONDRIAL ENZYME; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN KINASE C; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ADRENERGIC SYSTEM; ANIMAL CELL; CRYSTAL STRUCTURE; ENZYME PHOSPHORYLATION; EXCITATION CONTRACTION COUPLING; HEART CONTRACTION; HEART FAILURE; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART VENTRICLE WALL; MOUSE; NONHUMAN; OOCYTE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RABBIT; REVIEW; SIGNAL TRANSDUCTION; XENOPUS;

HUMANS; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84866923475     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.06.017     Document Type: Review

References (48)

1. Ashrafian H., Neubauer S. Metabolic modulation in heart failure: High time for a definitive clinical trial. Heart 2011, 97:267-268.
2. 3-adrenoceptors. Exp Physiol 2009, 94:400-411.
3. Baker J.G. Site of action of beta-ligands at the human beta1-adrenoceptor. J Pharmacol Exp Ther 2005, 313:1163-1171.
4. Baker J.G. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol 2010, 160:1048-1061.
5. + pump mediated by glutathionylation of its beta1 subunit. J Biol Chem 2011, 286:18562-18572.
6. Brennan J.P., Bardswell S.C., Burgoyne J.R., et al. Oxidant-induced activation of type I protein kinase A is mediated by RI subunit interprotein disulfide bond formation. J Biol Chem 2006, 281:21827-21836.
7. Bristow M.R. Treatment of chronic heart failure with β-adrenergic receptor antagonists: A convergence of receptor pharmacology and clinical cardiology. Circ Res 2011, 109:1176-1194.
8. + pump by reversal of an inhibitory oxidative modification. Circulation 2010, 122:2699-2708.
9. Cohn J.N., Pfeffer M.A., Rouleau J., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003, 5:659-667.
10. + pump regulation. Circ Res 2009, 105:185-193.
11. Francis S.H., Busch J.L., Corbin J.D., Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010, 62:525-563.
12. Gallogly M.M., Starke D.W., Mieyal J.J. Mechanistic and kinetic details of catalysis of thiol-disulfide exchange by glutaredoxins and potential mechanisms of regulation. Antioxid Redox Signal 2009, 11:1059-1081.
13. Geering K. FXYD proteins: New regulators of Na-K-ATPase. Am J Physiol Renal Physiol 2006, 290:F241-F250.
14. Goldstein D.S., Eisenhofer G., Kopin I.J. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 2003, 305:800-811.
15. Humphries K.M., Deal M.S., Taylor S.S. Enhanced dephosphorylation of cAMP-dependent protein kinase by oxidation and thiol modification. J Biol Chem 2005, 280:2750-2758.
16. Kamp T.J., Hell J.W. Regulation of cardiac l-type calcium channels by protein kinase A and protein kinase C. Circ Res 2000, 87:1095-1102.
17. + pump by decreasing baseline oxidative modification of its beta 1 pump subunit. Eur Heart J 2010, 31(Abstract Supplement):697. [abstract: P4074].
18. + increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation 2010, 121:1606-1613.
19. Kushnir A., Marks A.R. The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol 2010, 59:1-30.
20. + pump subunit to glutathionylation and oxidative inhibition depends on conformational state of pump. J Biol Chem 2012, 287:12353-12364.
21. 2+ cycling and new therapeutic approaches for heart failure. Circulation 2010, 121:822-830.
22. Massion P.B., Balligand J.L. Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): Lessons from genetically modified mice. J Physiol 2003, 546:63-75.
23. Mongillo M., Tocchetti C.G., Terrin A., et al. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 2006, 98:226-234.
24. Murphy E., Eisner D.A. Regulation of intracellular and mitochondrial sodium in health and disease. Circ Res 2009, 104:292-303.
25. Nabeebaccus A., Zhang M., Shah A.M. NADPH oxidases and cardiac remodelling. Heart Fail Rev 2011, 16:5-12.
26. Pieske B., Houser S.R., Hasenfuss G., Bers D.M. Sodium and the heart: A hidden key factor in cardiac regulation. Cardiovasc Res 2003, 57:871-872.
27. Pimentel D., Haeussler D.J., Matsui R., et al. Regulation of cell physiology and pathology by protein S-glutathionylation: Lessons learned from the cardiovascular system. Antioxid Redox Signal 2012, 16:524-542.
28. +-ATPase. FEBS Lett 2010, 584:2589-2595.
29. +-binding site in molecular dynamics simulations. J Biol Chem 2012, 287:15959-15965.
30. Rasmussen H.H., Figtree G.A., Krum H., Bundgaard H. The use of beta3-adrenergic receptor agonists in the treatment of heart failure. Curr Opin Investig Drugs 2009, 10:955-962.
31. Rasmussen H.H., Liu C., Hamilton E.J., Figtree G.A. Reversible oxidative modification: Implications for cardiovascular physiology and pathophysiology. Trends Cardiovasc Med 2010, 20:85-90.
32. Rozec B., Erfanian M., Laurent K., et al. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 2009, 53:1532-1538.
33. Shattock M.J. Phospholemman: Its role in normal cardiac physiology and potential as a druggable target in disease. Curr Opin Pharmacol 2009, 9:160-166.
34. + pump current in isolated rabbit ventricular myocytes using the whole-cell voltage-clamp technique: Inhibition of the pump by oxidant stress. Circ Res 1993, 72:91-101.
35. Shinoda T., Ogawa H., Cornelius F., Toyoshima C. Crystal structure of the sodium-potassium pump at 2.4 A resolution. Nature 2009, 459:446-450.
36. Sweadner K.J., Feschenko M.S. Predicted location and limited accessibility of protein kinase A phosphorylation site on Na-K-ATPase. Am J Physiol Cell Physiol 2001, 280:C1017-C1026.
37. Sweadner K.J., Rael E. The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression. Genomics 2000, 68:41-56.
38. Toyoshima C., Kanai R., Cornelius F. First crystal structures of Na+,K+-ATPase: New light on the oldest ion pump. Structure 2011, 19:1732-1738.
39. Tulloch L.B., Howie J., Wypijewski K.J., et al. The inhibitory effect of phospholemman on the sodium pump requires its palmitoylation. J Biol Chem 2011, 286:36020-36031.
40. Walker J.S., Walker L.A., Margulies K., et al. Protein kinase A changes calcium sensitivity but not crossbridge kinetics in human cardiac myofibrils. Am J Physiol Heart Circ Physiol 2011, 301:H138-H146.
41. Wang S.B., Foster D.B., Rucker J., et al. Redox regulation of mitochondrial ATP synthase: Implications for cardiac resynchronization therapy. Circ Res 2011, 109:750-757.
42. Ward N.E., Stewart J.R., Ioannides C.G., O'Brian C.A. Oxidant-induced S-glutathiolation inactivates protein kinase C-alpha (PKC-alpha): A potential mechanism of PKC isozyme regulation. Biochemistry 2000, 39:10319-10329.
43. + pump and inhibits its activity. J Biol Chem 2010, 285:13712-13720.
44. + pump via PKC-dependent activation of NADPH oxidase. Am J Physiol Cell Physiol 2009, 296:C693-C700.
45. Xamoterol in severe heart failure: The xamoterol in severe heart failure study group. Lancet 1990, 336:1-6. Xamoterol in Severe Heart Failure Study Group.
46. Xiang Y.K. Compartmentalization of beta-adrenergic signals in cardiomyocytes. Circ Res 2011, 109:231-244.
47. Zhang M., Kass D.A. Phosphodiesterases and cardiac cGMP: Evolving roles and controversies. Trends Pharmacol Sci 2011, 32:360-365.
48. Zweier J.L., Chen C.A., Talukder M.A. Cardiac resynchronization therapy and reverse molecular remodeling: Importance of mitochondrial redox signaling. Circ Res 2011, 109:716-719.